<DOC>
	<DOCNO>NCT02477969</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , phase III clinical study enroll approximately 564 T2DM patient screen inadequately control blood glucose （7.0 % ≤HbA1c≤10.5 % randomization）despite least 8 week metformin monotherapy stable doses（≥1500 mg/day ) .</brief_summary>
	<brief_title>Efficacy Safety Study PEX168 Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin</brief_title>
	<detailed_description>Subjects randomize receive either PEX168 100μg , 200μg PEX 168 Dummy Injection add-on metformin hydrochloride . The baseline HbA1c level （HbA1c≤8.5 % HbA1c &gt; 8.5）is design stratification factor base dynamic randomization perform . This study consist 4 periods： Period 1：Up 3 week screen period . Period 2：A 4-week PEX168 dummy injection run-in period . Period 3：A 52-week treatment period ( include 24-week core treatment period 28-week extended treatment period ) . Period 4 : A 30-day safety follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria： 1 . Type 2 diabetes mellitus confirm 1999 WHO criteria 2 . Men woman 3 . Age sign ICF≥18 year ≤78 year 4 . Body mass index ( BMI ) 2040 Kg/m2 5 . At least 8 week metformin monotherapy receive prior screen 6 . No glucoselowering medication metformin receive within 8 week prior screen 7 . 7.5 % ≤HbA1c≤11.0 % screening（local centralized test 7.0 % ≤HbA1c≤10.5 % randomization ( centralized test ) 8 . Ability understand procedure approach study , willingness complete study strict compliance protocol voluntarily sign ICF Exclusion criterion ( subject exclude meeting following ) 1 . Investigator suspect subject allergy study drug 2 . Use following medication therapy prior screen GLP1 receptor agonist , GLP1 analogues , DPP4 inhibitor incretin analogue Growth hormone therapy within 6 month prior screen History drug abuse alcohol abuse Participation clinical trial pharmaceutical product medical device within 3 month prior screen Prolonged ( least 7 consecutive day ) intravenous , oral intraarticular treatment corticosteroid within 2 month prior screen Use weight control agent surgery might lead unstable weight within 2 month prior screen , subject currently weight loss plan maintenance phase Any medication use prior screen investigator 's discretion may confound interpretation efficacy safety data , use medication may cause common toxicity major organ , include Chinese herbal medicine 3 . History evidence follow condition prior screening： Type 1 diabetes mellitus , single gene mutation DM , DM associate pancreatic injury， secondary DM , e.g. , DM secondary Cushing syndrome acromegalia History hypertension SBP＞160 mmHg and/or DBP＞100 mmHg despite glucoselowering agent stable dose ( least 4 week ) History acute/chronic pancreatitis , history symptomatic cholecystopathy , risk factor pancreatitis include pancreatic injury History myeloid Ccell carcinoma , history multiple endocrine neoplasm （MEN） 2A 2B syndrome , relate familiar history Clinically significant gastric empty disorder , severe chronic gastrointestinal disorder , prolong treatment peristalsis stimulant , gastrointestinal surgery History severe hypoglycemic episode , severe hypoglycemia without symptom Significant hematological disorder , disease may lead hemolysis unstable RBC Severe diabetic complication ( e.g. , macrovascular microvascular complication ) opinion investigator make subject suitable participate study Tumors organ system treat within 5 year prior screen , regardless whether evidence relapse metastasis , exception local basal cell carcinoma skin Coronary angioplasty , coronary stenting , coronary artery bypass , uncompensated heart failure （NYHA Class III IV） , stroke transient cerebral ischemic attack , unstable angina , myocardial infarction , persistent clinically significant arrhythmia , experience within 6 month prior screen Acute metabolic complication ( e.g. , ketoacidosis , lactic acidosis , hyperosmolar coma ) within 6 month prior screen Thyroid dysfunction treat unstable therapeutic dos ( e.g. , thioureas , thyroid hormone ) within 6 month prior screen Blood lipid disorder treat unstable therapeutic dos ( e.g. , statin , fibrates ) within 6 month prior screen Any severe trauma severe infection may interfere BG control within 1 month prior screen 4 . Laboratory indicator meet follow criterion prior screen ( test meeting criterion must repeat within 3 work day confirmation ) ALT＞2.5×ULN and/or AST＞2.5×ULN and/or total bilirubin＞2.5×ULN Hemoglobin≤100 g/L Serum creatinine＞1.5×UNL eGFR &lt; 45 ml/min/1.73 m2 eGFR calculate as：186.3 × [ （Serum Creatinine（mmol/L）/88.4） ] −1.154 × [ Age ( year ) ] − 0.203 × 1.223 × 0.742 （Females） ×1（Males） Serum thyroidstimulating hormone（TSH） reference range assess clinically significant investigator Fasting TGL＞5.64 mmol/L（500 mg/dl ) Blood amylase urine amylase &gt; ULN assess clinically significant investigator Any clinically significant laboratory abnormality investigator 's discretion may confound interpretation efficacy safety data 5 . Clinically significant 12lead ECG abnormality , e.g. , Grade II III atrial ventricular block （with exception right bundle branch block），long QT syndrome QTc &gt; 500ms 6 . Blood donation loss≥400 mL，or receipt blood donation within 4 week prior screen 7 . Pregnant lactate woman , men woman childbearing potential willing take contraceptive measure study 8 . Any condition subject investigator 's discretion may compound interpretation efficacy safety data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>